May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 28, 2025

One Third Report HPPD After Psychedelics

Delusional ideation was found to be reduced one month after psychedelic use, researchers reported in a prospective cohort of 654 participants.

Conexiant

April 25, 2025

Opioid Use High in Adults With Cerebral Palsy 

Over 50% exhibited a mixed pain phenotype, researchers wrote, linking cerebral palsy pain types to increased opioid use and treatment complexity.

Conexiant

April 23, 2025

Long-Term EEG Monitoring Now Authorized in the United States

The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.

Conexiant

April 22, 2025

Heavy Metals Found in Toothpaste

There are some "heavy metals that are essential in small quantities but could result in adverse effects if present in excess."

Conexiant

April 21, 2025

New Findings Show No Difference in IGE Treatment Strategies

A study found no statistically significant differences in treatment failure rates between substitution monotherapy and add-on therapy for women with idiopathic generalized epilepsy, indicating both options are viable.

Conexiant

April 18, 2025

Intranasal Diazepam Gains Expanded Approval for Pediatric Patients

“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”

Conexiant

April 17, 2025

Climate Identified as Key Virus Driver

Researchers found Oropouche virus to be underreported during a large-scale study across Latin America, with climate emerging as the primary driver of transmission risk.

Conexiant